ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC’s botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.
Related news for (ABVC)
- Breaking News: MoBot’s Latest Update as of 07/11/25 04:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/08/25 01:00 PM
- Today’s Top Performers: MoBot’s Market Review 07/07/25 02:00 PM
- Today’s Top Performers: MoBot’s Market Review 07/02/25 03:00 PM
- Breaking News: MoBot’s Latest Update as of 04/07/25 10:00 AM